Company Filing History:
Years Active: 2011
Title: Steffen Scheithauser: Innovator in Pharmaceutical Formulations
Introduction
Steffen Scheithauser is a notable inventor based in Dresden, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms. His innovative work focuses on enhancing the delivery and effectiveness of active ingredients in medication.
Latest Patents
Steffen Scheithauser holds a patent for an "Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient." This patent describes a method for producing oral pharmaceutical compositions containing propiverine, which can range from 4 mg to 60 mg. The compositions are designed to provide a prolonged release of the active agent, utilizing a blend of the active ingredient and acidic substances with a pK value of less than 6.65. These formulations are either coated with a retarding layer or embedded in a matrix that may also have additional retarding coatings.
Career Highlights
Steffen Scheithauser is associated with Apogepha Arzneimittel GmbH, where he applies his expertise in pharmaceutical development. His work has contributed to advancements in medication delivery systems, improving patient outcomes through innovative formulations.
Collaborations
Steffen collaborates with esteemed colleagues such as Thomas Gramatte and Peter Gruber. Their combined efforts in research and development have furthered the understanding and application of pharmaceutical technologies.
Conclusion
Steffen Scheithauser's contributions to the pharmaceutical industry exemplify the importance of innovation in medication delivery. His patent for an extended-release oral dosage form highlights his commitment to improving therapeutic efficacy. Through his work at Apogepha Arzneimittel GmbH and collaborations with fellow researchers, he continues to make a significant impact in the field.